Sanofi(US:SNY) Xin Lang Cai Jing·2026-02-03 23:20Group 1 - The application for sodium valproate oral solution by Sanofi (Hangzhou) Pharmaceutical Co., Ltd. has been accepted, with acceptance number CYHB2600219, on February 4, 2026 [1] - Sanofi (Hangzhou) Pharmaceutical Co., Ltd. was established on November 30, 1995, and operates in the chemical pharmaceutical raw material manufacturing industry [1] - The company is a medium-sized foreign-invested limited liability company with a registered capital of 28.8 million USD and a paid-in capital of 28.8 million USD [1] Group 2 - The major shareholder is Sanofi Pharmaceutical Development Company from France, holding 75% with a contribution of 21.6 million USD, while Sanofi (China) Investment Co., Ltd. holds 25% with a contribution of 7.2 million USD [1] - The company has 498 insured employees and is located at 325 Jiangling Road, Binjiang District, Hangzhou, Zhejiang Province [1]